Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma
Photoimmunotherapy for head and neck cancer (HNC-PIT) is a newly developed locoregional treatment targeting the epidermal growth factor. This treatment consists in administering cetuximab sarotalocan sodium that conjugates cetuximab with the dye IRdye700DX, which is activated by near-infrared ray illumination at 690 nm. HNC-PIT has been conditionally approved in Japan in September 2020 for the treatment of unresectable locally advanced or unresectable locoregionally recurrent HNC. However, its outcomes on the local recurrence of the nasopharyngeal squamous cell carcinoma (NPSCC) remain undetermined.
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Go Omura, Yoshitaka Honma, Yoshifumi Matsumoto, Takeshi Shinozaki, Mai Itoyama, Kohtaro Eguchi, Toshihiko Sakai, Kazuki Yokoyama, Takane Watanabe, Akihiro Ohara, Ken Kato, Seiichi Yoshimoto Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | ENT & OMF | Erbitux | Head and Neck Cancer | Japan Health | Laryngeal Cancer | Nasopharyngeal Cancer | Skin Cancer | Sodium | Squamous Cell Carcinoma